Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | POLG | P54098 | 1/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 4/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.50 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.50 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14660974 | 1.00 | POLB (0.55) | POLBPOLGDNMT1P2RY2P2RY4 | |
| SCHEMBL20906737 | 0.98 | POLG (0.54) | POLBPOLGDNMT1P2RY2P2RY4 | |
| SCHEMBL15201233 | 0.98 | POLG (0.54) | POLBPOLGDNMT1P2RY2P2RY4 | |
| SCHEMBL15810651 | 0.98 | POLG (0.54) | POLBPOLGDNMT1P2RY2P2RY4 | |
| SCHEMBL336251 | 0.98 | POLG (0.54) | POLBPOLGDNMT1P2RY2P2RY4 | |
| SCHEMBL22300298 | 0.98 | POLG (0.54) | POLBPOLGDNMT1P2RY2P2RY4 | |
| SCHEMBL336318 | 0.92 | TYMS (0.55) | POLBDNMT1DNMT3BTYMS | |
| SCHEMBL1331043 | 0.92 | TYMS (0.55) | POLBDNMT1DNMT3BTYMS | |
| SCHEMBL15472378 | 0.92 | P2RY2 (0.51) | POLBPOLGDNMT1P2RY2P2RY4 | |
| Triphosphate SCHEMBL28135309 | 0.90 | DNMT1 (0.58) | POLBPOLGDNMT1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125749-A1 | HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12595509-B2 | Synthetic nucleic acid spike-ins | KARIUS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260072019-A1 | METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE PORE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12553085-B2 | Sequencing kit | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20260043809-A1 | AFFINITY CAPTURE REAGENTS FOR MASS SPECTROMETRY | UNIV OXFORD INNOVATION LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260028379-A1 | MUTANT PORE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-01-29 | — | — | US | disclosed |
| US-12509721-B2 | Methods and systems for characterizing analytes using nanopores | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-12-30 | — | — | US | disclosed |
| EP-4665753-A1 | ARMOURED REGULATORY T CELL | King's College London (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250361502-A1 | Promoters And Compositions | UNIV OXFORD INNOVATION LTD (GB) | 2025-11-27 | — | — | US | disclosed |
| EP-4643130-A1 | AFFINITY CAPTURE REAGENTS FOR MASS SPECTROMETRY | Oxford University Innovation Limited (GB) | 2025-11-05 | — | — | EP | disclosed |
| WO-2014170661-A1 | STRAIN OF DEFORMED WING VIRUS (DWV) | THE UNIVERSITY OF WARWICK (GB) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014102539-A1 | DELIVERY METHOD USING MESOPOROUS SILICA NANOPARTICLES | ISIS INNOVATION LIMITED (GB) | 2014-07-03 | — | — | WO | disclosed |
| EP-2737084-A1 | HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES | Oxford Nanopore Technologies Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| WO-2014072703-A1 | QUADRUPLEX METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014064444-A1 | DROPLET INTERFACES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2014-05-01 | — | — | WO | disclosed |
| WO-2013153359-A1 | MUTANT LYSENIN PORES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2013-10-17 | — | — | WO | disclosed |
| WO-2013121224-A1 | ANALYSIS OF MEASUREMENTS OF A POLYMER | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013121201-A1 | APTAMER METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013014451-A1 | HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260072019-A1 | METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE PORE | NUP210, EPCAM, PHAX | POLB 1826/4885POLG 2862/4885DNMT1 2398/4885 |
| US-12509721-B2 | Methods and systems for characterizing analytes using nanopores | DNA2, MTREX, DDX21 | POLB 48/4885POLG 109/4885DNMT1 123/4885 |
| US-20260043809-A1 | AFFINITY CAPTURE REAGENTS FOR MASS SPECTROMETRY | DDX6, DDX1, DDB1 | POLB 647/4885POLG 897/4885DNMT1 679/4885 |
| US-12553085-B2 | Sequencing kit | PHAX, TIA1, POLM | POLB 684/4885POLG 1113/4885DNMT1 1190/4885 |
| US-20260125749-A1 | HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES | POLRMT, PITPNB, NUP205 | POLB 81/4885POLG 528/4885DNMT1 959/4885 |
| US-20260028379-A1 | MUTANT PORE | PTMS, NUP50, NUP205 | POLB 2195/4885POLG 1615/4885DNMT1 2912/4885 |
| US-12595509-B2 | Synthetic nucleic acid spike-ins | SPOUT1, NOP2, METTL16 | POLB 594/4885POLG 2216/4885DNMT1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.